Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $7.00.

PGEN has been the topic of several recent analyst reports. HC Wainwright dropped their target price on Precigen from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, August 15th. JMP Securities cut their target price on Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 15th. Stifel Nicolaus boosted their target price on Precigen from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, June 3rd. Finally, StockNews.com upgraded shares of Precigen to a “sell” rating in a research note on Thursday, August 1st.

Precigen Stock Performance

Shares of PGEN opened at $1.00 on Tuesday. Precigen has a 1 year low of $0.84 and a 1 year high of $1.93. The stock has a market capitalization of $252.37 million, a PE ratio of -2.56 and a beta of 1.67. The stock has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $1.41.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Precigen had a negative return on equity of 90.99% and a negative net margin of 3,084.55%. The firm had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $1.28 million. Analysts predict that Precigen will post -0.42 EPS for the current year.

Insider Activity

In other news, SVP Jeffrey Thomas Perez purchased 58,823 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were purchased at an average price of $0.85 per share, for a total transaction of $49,999.55. Following the purchase, the senior vice president now directly owns 743,097 shares of the company’s stock, valued at approximately $631,632.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 44.90% of the company’s stock.

Institutional Trading of Precigen

Large investors have recently bought and sold shares of the business. ClariVest Asset Management LLC raised its holdings in shares of Precigen by 2.9% in the second quarter. ClariVest Asset Management LLC now owns 492,152 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 13,752 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Precigen by 40.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 16,486 shares during the last quarter. AQR Capital Management LLC lifted its position in Precigen by 56.7% during the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 18,097 shares during the period. Fortis Group Advisors LLC acquired a new stake in Precigen during the 1st quarter worth approximately $28,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Precigen by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 47,829 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 19,041 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.